

TargED Biopharmaceuticals Appoints Rob Dekker as Vice President CMC

Utrecht, the Netherlands, March 5, 2026 - TargED Biopharmaceuticals B.V., a clinical-stage biotechnology company developing next-generation targeted treatments for thrombotic diseases, has appointed Rob Dekker as Vice President CMC (Chemistry, Manufacturing and Controls), effective 1 March 2026. In this role, Rob will lead CMC strategy and execution across TargED's development programs and will be a member of the management team.

Rob brings nearly three decades of experience in biopharmaceutical development and manufacturing, with extensive expertise in translating manufacturing science into compliant, scalable GMP operations. He has led cross-functional CMC programs from early clinical development through BLA/MAA submissions and commercial manufacturing, integrating process development, validation, and regulatory strategy across complex product modalities including vaccines, biologics, and cell therapies.

"TargED is entering an important phase as we advance TGD001 through clinical development," said Kristof Vercruysse, CEO of TargED Biopharmaceuticals. "Rob's deep CMC leadership experience, combined with his proven track record in regulatory strategy and GMP operations, will be instrumental in strengthening our development and manufacturing capabilities as we prepare for later-stage clinical trials and future commercialization."

Rob most recently served as CMC Leader/Director at J&J Innovative Medicine, where he led CMC activities for vaccine programs, including advancing an RSV vaccine from early clinical development through BLA completion and supporting late-stage development of a multivalent bacterial vaccine in collaboration with Sanofi. Earlier, he held senior CMC leadership roles at Teva Pharmachemie, Kiadis Pharma (later acquired by Sanofi), OctoPlus (now Delpharm), and Biogen. Rob holds an M.Sc. in Medical Biology from the Vrije Universiteit Amsterdam.

"I am excited to join TargED at this pivotal stage," said Rob Dekker. "TargED's first-in-class targeted thrombolytic has the potential to redefine how thrombotic diseases such as ischaemic stroke and thrombotic microangiopathies are treated. I look forward to working with the team to further build a strong CMC foundation and ensure reliable, high-quality manufacturing to support the continued advancement of TGD001."

About TargED Biopharmaceuticals

TargED Biopharmaceuticals B.V. is a clinical-stage biotechnology company pioneering targeted enzyme delivery for improved treatment of thrombotic diseases. Founded in 2020 as a spin-off from the University Medical Center Utrecht, the company has raised more than €60 million to advance its pipeline and was awarded a prestigious blended finance grant from the European Innovation Council (EIC) Accelerator Program in 2025. For more information, please visit www.targedbio.com

About TGD001

TGD001 is a first-in-class, targeted thrombolytic designed to treat a broad range of thrombotic events. As an antibody-enzyme fusion protein, it binds to von Willebrand factor (VWF) and promotes site-specific clot breakdown via plasminogen activation. Unlike currently approved therapies, TGD001 leverages the ubiquitous presence of VWF in all clots, enabling broad clot lysis by degrading both VWF and fibrin. TGD001 has been evaluated in a Phase 1 first-in-human clinical trial and will be further developed for the treatment of acute ischemic stroke (AIS) and thrombotic microangiopathies (TMAs), including immune thrombotic thrombocytopenic purpura (iTTP).

Media Contact: info@targedbio.com